A Study of Armored CAR T Cells in People With Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór neuroendokrynny z markerem DLL3 (w tym rak płuca małokomórkowy, raki żołądkowo-jelitowe, prostaty i innych)
- •Ukończone co najmniej jedno leczenie chemioterapią lub immunoterapią, bez skutku lub z powodu nietolerancji
- •Wiek powyżej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-1)
- •Prognoza przeżycia co najmniej 12 tygodni
- •Co najmniej jeden zmierzalny guz widoczny w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)
Commack, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, United States
Memorial Sloan Kettering Cancer Center @ Nassau (Limited Protocol Activities)
Uniondale, United States
Trial contact
Adam Schoenfeld, MD
Ritesh Kotecha, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.